Detection of serum levels of MMP-9 and VEGF in patients with bladder cancer.
- Author:
Kao-peng GUAN
1
;
Shu-kun HOU
;
Zheng YAN
;
Hai-yun YE
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Humans; Matrix Metalloproteinase 9; blood; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; blood; pathology; Vascular Endothelial Growth Factor A; blood
- From: Chinese Journal of Surgery 2003;41(6):430-432
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect serum levels of MMP-9 and VEGF in patients with bladder cancer.
METHODSSerum levels of MMP-9 and VEGF in 58 patients with bladder cancer and 45 healthy controls were measured by sandwich-ELISA.
RESULTSSerum levels of MMP-9 and VEGF (737.12 micro g/L and 1148.88 ng/L) were significantly higher in the cancer patients than those of controls (423.51 micro g/L and 846.96 ng/L, P < 0.01). The serum levels were associated with tumor stage and grade. In patients with invasive cancer, the levels were significantly higher than those of superficial cancer (P < 0.01). Patients with distant metastasis had significantly higher levels of MMP-9 and VEGF than those with localized invasion (P < 0.01). But there was no significant difference between patients with superficial cancer and controls. Patients with G(3) tumors had significantly higher levels of MMP-9 and VEGF than those of patients with G(1) and G(2) tumors (P < 0.01).
CONCLUSIONSElevated MMP-9 and VEGF levels are associated with a high stage and grade of bladder cancer and they may serve as markers of tumor progression in the future.
